What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Schering-Plough Corporation's financial results for the fourth quarter and the full fiscal year of 2004. It makes available the company's official press release and supplemental financial data concerning these results.

What are the main risks highlighted by Schering-Plough in this filing?

Schering-Plough highlights a broad range of risks, including intense competition, pricing pressures from managed care organizations and government agencies, potential impacts of U.S. healthcare legislation like the Medicare Prescription Drug, Improvement and Modernization Act of 2003, uncertainties surrounding patent disputes, challenges in regulatory approval processes, potential issues with product development and manufacturing, and adverse outcomes from litigation.

Does this filing provide specific financial numbers for Q4 2004 and FY 2004?

This 8-K filing itself does not contain the specific financial figures. Instead, it announces that the company issued a press release and provided supplemental financial data (Exhibits 99.1 and 99.2) containing these results. Investors would need to refer to those accompanying exhibits or the earnings teleconference for the detailed financial numbers.

Is Schering-Plough obligated to update its forward-looking statements?

No, the company explicitly states that it "does not assume the obligation to update any forward-looking statement." This means that investors should not expect the company to provide updates if circumstances change or if future events differ from the projections made in this report.

MRK 8-K: Earnings & Results

Summary

This 8-K filing from Schering-Plough Corporation, dated January 25, 2005, primarily serves to report the company's financial results for the fourth quarter and full year of 2004. The filing includes a press release and supplemental financial data as exhibits, offering investors a snapshot of the company's performance. While the specific financial figures are not detailed within this document itself, it indicates that these results were publicly disseminated on the filing date. Furthermore, the report contains a comprehensive "Disclosure Notice for Forward Looking Statements." This section is crucial for investors as it outlines the inherent uncertainties and risks associated with the company's future projections. It details numerous factors that could materially impact Schering-Plough's actual financial and operational performance, ranging from competitive pressures and pricing challenges to regulatory hurdles, patent disputes, product development risks, and macroeconomic conditions. Investors should pay close attention to these risk factors when evaluating the company's outlook.

Key Highlights

1Schering-Plough Corporation filed an 8-K on January 25, 2005, to report its financial results for the fourth quarter and full year 2004.
2The filing includes a press release (Exhibit 99.1) and supplemental financial data (Exhibit 99.2) related to the reported financial results.
3The document emphasizes a significant section dedicated to "Forward Looking Statements," alerting investors to potential risks and uncertainties.
4Key risk factors mentioned include competitive landscape, pricing pressures from various stakeholders, potential impacts of U.S. legislation (e.g., Medicare modernization), patent uncertainties, and regulatory approval processes.
5Product development risks, post-marketing issues, and potential challenges with major products like CLARITIN, CLARINEX, and INTRON A are highlighted.
6The company also acknowledges risks related to manufacturing issues, litigation outcomes, and general economic factors.
7Schering-Plough explicitly states it does not assume an obligation to update any forward-looking statements made in the report.

Merck & Co., Inc. 8-K Report, Financial Results (Jan 25, 2005)

Summary

Key Highlights

Frequently Asked Questions